Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bugs may hold key to menopause nutrition

NCT ID NCT07182370

Knowledge-focused Sponsor: National Research Council, Spain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how the gut microbiome influences the way menopausal women process plant compounds like resveratrol and isoflavones. Researchers will give 90 women either plant extract capsules or a placebo for eight weeks, then measure changes in heart health markers and quality of life. The goal is to understand why women respond differently to these nutrients, paving the way for personalized diet advice during menopause.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
plant extracts (resveratrol, ellagic acid, isoflavones)
What this could lead to
If successful, this could lead to personalized nutrition plans for menopausal women to improve well-being and reduce heart disease risk.
What could go wrong
This is a small, early-stage study (90 participants) focused on understanding biological markers, not proving a treatment works. Results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jan 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 57 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 45 to 57 years. * Diagnosed menopause (defined as 12 consecutive months without menstruation). * Presenting at least one climacteric symptom (hot flashes and/or sweating episodes and/or low mood and/or irritability and/or decreased libido and/or insomnia and/or joint/muscle pain). * Body Mass Index (BMI) ≥ 18 kg/m². * Adequate cultural level and ability to understand the clinical study. * Willing to voluntarily participate in the study and provide written informed consent. Exclusion Criteria: * Presence of severe, chronic-degenerative, or psychiatric conditions, or any contraindication to the use of nutritional supplements. * History of major gastrointestinal surgery. * Swallowing difficulties (e.g., inability to ingest capsules). * BMI \< 18 kg/m² or \> 30 kg/m². * Currently following a weight-loss regimen. * Known or suspected allergy or intolerance to red clover extract, resveratrol (grape, wine), soy, or pomegranate. * Use of chronic preventive medication for cholesterol, glucose, blood pressure, etc. (e.g., statins, metformin, beta-blockers). * Use of antibiotics within one month prior to study initiation. * Undergoing hormone replacement therapy. * Alcohol consumption exceeding 1 beer or 1 glass of wine per day. * Regular use of dietary supplements (e.g., probiotics, isoflavones, resveratrol, others). * Following a vegetarian diet. * Current smoker or having smoked at any time during the past year. * Individuals unwilling to comply with study guidelines.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular risk are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Endotoxemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular risk Menopause related conditions

Contacts and locations

Locations

  • Centro de Edafología y Biología Aplicada del Segura (CEBAS-CSIC)

    Murcia, Murcia, 30100, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.